Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Aims: Dulaglutide, a once weekly GLP‐1 receptor agonist, is approved at two doses (1.5 and 0.75 mg) for treatment of type 2 diabetes (T2D). Two higher doses of dulaglutide (3.0 and 4.5 mg) were evaluated for safety and efficacy to determine whether these doses warrant further study for improved control of glucose and body weight. Materials and methods: This 18‐week, double‐blind, phase 2 trial randomized 318 patients with T2D using ≥1500 mg metformin, to receive subcutaneous injection of placebo (n = 82), dulaglutide 1.5 mg (n = 81), dulaglutide 3.0 mg (n = 79) or dulaglutide 4.5 mg (n = 76). The primary objective was superiority of dulaglutide doses over placebo in reduction of HbA1c at 18 weeks. Secondary objectives included superiority of dulaglutide over placebo in change from baseline in body weight and fasting serum glucose (FSG) at 18 weeks. Investigational doses of dulaglutide were compared to the 1.5 mg dose as an exploratory objective. Results: HbA1c reduction at 18 weeks was significantly greater with dulaglutide vs placebo (placebo, −0.44% ± 0.10% [−4.8 ± 1.1 mmol/mol]; dulaglutide 1.5 mg, −1.23% ± 0.10% [−13.5 ± 1.1 mmol/mol]; dulaglutide 3.0 mg, −1.31% ± 0.10% [−14.3 ± 1.1 mmol/mol]; dulaglutide 4.5 mg, −1.40% ± 0.10% [−15.3 ± 1.1 mmol/mol]; P < 0.001, each dose), as were changes in body weight (placebo, −1.6 ± 0.39 kg; dulaglutide 1.5 mg, −2.8 ± 0.39 kg; dulaglutide 3.0 mg, −3.9 ± 0.39 kg; dulaglutide 4.5 mg, −4.1 ± 0.41 kg; P < 0.001, each dose). All three dulaglutide doses significantly reduced FSG from baseline (1.5 mg, −36.2 ± 4.7 mg/dL [−2.0 ± 0.3 mmol/L]; 3.0 mg, −34.5 ± 4.5 mg/dL [−1.9 ± 0.3 mmol/L]; 4.5 mg, −38.0 ± 4.7 mg/dL [−2.1 ± 0.3 mmol/L]) vs placebo (−12.4 ± 4.5 mg/dL [−0.7 ± 0.3 mmol/L]) ( P < 0.001, all). Safety profiles of the higher doses were consistent with the established safety profile for dulaglutide. Gastrointestinal events were mostly mild to moderate, and was dose‐related for nausea. Conclusion: All three dulaglutide doses were superior to placebo in improving glycaemic control and reducing body weight in participants with T2D using metformin. The potential for doses of dulaglutide of 3.0 and 4.5 mg to provide additional glycaemic benefit and weight reduction with an acceptable safety profile, compared with the 1.5 mg dose, warrants further study in a phase 3 trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Events of hypoglycaemia were collected as described by Seaquist et al.20 (documented symptomatic, asymptomatic, probable symptomatic, severe, nocturnal and total).”
MethodGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284 · cited 1×
“Because of their acceptable tolerability, these doses do not require dose escalation to reduce gastrointestinal (GI) side effects at initiation.(5,12) Dose assessment during the dulaglutide development programme included doses up to 8 mg without dose escalation at initiation; however, it was recommened by a data safet…”
BackgroundGLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199
Self-citationFrias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Whitley, H. P., Trujillo, J. M., & Neumiller, J. J. (2023) · Clinical Diabetes · doi:10.2337/cd23-0023 · Cited by 132
Metadata
- Authors
- Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-06-03
- Volume
- 21
- Issue
- 9
- Pages
- 2048-2057
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2943546226
- Cited by
- 46
- References
- 15
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin. https://app.cochat.ai/papers/10.1111/dom.13764
- The paper
- Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z. (2019). Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13764
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.